592542-50-2 Usage
Description
(E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine is a complex organic molecule characterized by its unique structure, which includes a sulfone and an amine functional group. It is derived from aromatic compounds such as styryl sulfoxides and amines, and features methoxy and methyl substituents that contribute to its reactivity and potential applications.
Uses
Used in Medicinal Chemistry:
(E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique molecular structure and reactivity. Its ability to form different types of chemical bonds makes it a valuable building block for the development of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine serves as a versatile reactant for the creation of a wide range of organic compounds. Its functional groups and substituents allow for various synthetic transformations, making it a useful tool for chemists working on the development of novel organic molecules.
Used in Pharmaceutical Research and Drug Development:
(E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine is used as a potential target for pharmaceutical research and drug development. Its unique molecular structure and reactivity make it an interesting candidate for the discovery of new therapeutic agents. (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine's potential biological activities could be harnessed to develop innovative treatments for various diseases and conditions.
Used in the Chemical Industry:
In the chemical industry, (E)-2',4',6'-triMethoxystyryl-4-Methoxy-3-aMinobenzylsulfone, (E)-5-((2,4,6-triMethoxystyrylsulfonyl)Methyl)-2-MethoxybenzeneaMine may be utilized as a specialty chemical for the production of various products, such as dyes, pigments, and other materials that require its specific structural features. Its unique properties could be exploited to create new products with improved performance characteristics.
Check Digit Verification of cas no
The CAS Registry Mumber 592542-50-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,9,2,5,4 and 2 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 592542-50:
(8*5)+(7*9)+(6*2)+(5*5)+(4*4)+(3*2)+(2*5)+(1*0)=172
172 % 10 = 2
So 592542-50-2 is a valid CAS Registry Number.
592542-50-2Relevant articles and documents
2,4,6-TRIALKOXYSTRYL ARYL SULFONES, SULFONAMIDES AND CARBOXAMIDES, AND METHODS OF PREPARATION AND USE
-
, (2017/02/28)
Compounds according to Formula (I) are provided and salts thereof, wherein R1, R2, R33, R4, R5, R6, R13, A, X and Y are as defined herein. Methods for preparing compounds of Form
Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity
Reddy, M. V. Ramana,Venkatapuram, Padmavathi,Mallireddigari, Muralidhar R.,Pallela, Venkat R.,Cosenza, Stephen C.,Robell, Kimberly A.,Akula, Balaiah,Hoffman, Benjamin S.,Reddy, E. Premkumar
, p. 6254 - 6276 (2011/11/01)
Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.
FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES
-
Page/Page column title page; 55-57; 1/2, (2008/12/07)
Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell prolif
